Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaTyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementDasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsCardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patientsVirus interactions with endothelial cell receptors: implications for viral pathogenesis.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaVEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeabilityMonitoring response and resistance to treatment in chronic myeloid leukemia.Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.Dasatinib-related chylothoraxDifferential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III studyDasatinib-induced pleural effusion: Chylothorax, an option to consider.Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicityA critical role for Lyn kinase in strengthening endothelial integrity and barrier function.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.Development of an effective therapy for chronic myelogenous leukemiaTreatment options for chronic myeloid leukemia.Management of the new patient with CML in chronic phase.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.Incidence and risk factors of pleural effusions in patients with POEMS syndrome.First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?Chronic myeloid leukemia: First-line drug of choice.Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.Pleural effusion: a rare side effect of nilotinib-a case report.
P2860
Q26749324-21FF8296-EFF4-4CA2-B621-3819C9E48357Q28075963-463E3D36-61C8-4059-88FD-CC0B0C765B27Q28079372-A54D2386-7366-41DA-9476-B391CC0C33C6Q30884142-DFBE625E-9030-40F9-868C-83A5F7EF991AQ33401360-1196BAF8-3F4B-498F-87A2-26A78D98C2DDQ33404602-613B83CC-523D-41AA-AC3C-1E0980724D6DQ33798573-8C936450-F48E-4D51-A409-7C1E58CAF66DQ34388874-0475B843-7613-4AB9-8C4D-A4088F8CF547Q34522789-140D1356-7AE9-4107-958E-C5D55C7E4C2FQ34741912-EEB5F9AF-C1CC-4F24-8217-328B3351603AQ34761663-9EB7FA40-AEDB-474C-B8CB-75304E145BE5Q35194464-BC449446-0D81-471A-BAA0-D305A4D75B5AQ35265868-BCA54682-93BA-4E19-B4CC-9FA9F2661A2AQ35631562-ED259512-4EEF-4DB2-B5CF-51D4B0514CCDQ36933601-05B97100-A7F6-46B9-8F2B-EF253B1AF402Q37350583-9C62A45E-9BEE-4AA5-B903-1A54B78EBA6BQ37352396-9CD00EB9-E8A3-46A5-A0BB-711FB822EC4CQ37390244-1EF7A15C-BB4A-455E-8811-134507363E05Q37781050-CF12D87F-FA9C-4E24-B59D-B1B1960DE0D3Q37791429-A90D2705-BB4B-4351-94FA-06B10418BDF5Q37870181-F9B58083-11C2-48C2-9467-B5D92597A1ECQ37966917-E1B72532-339D-410C-8319-617C5087CD76Q37994805-550A3934-2C35-4E72-ADAD-91A20D5C6FCEQ38079151-56FCCB95-2194-4A8A-B8B1-6C2ED6F5617BQ38095848-E3196060-EBE8-41AA-9B89-35829C0A86BAQ38128723-8316B6CE-5DFF-4881-A894-03D65118FED5Q38138480-5E662628-1F85-4409-86F3-0CCB61D8BC40Q38148243-E1B41C97-EAF9-4AFD-A23D-D43C6D4E6985Q38187361-766D9209-916F-4AFD-967B-CAEC5646DA35Q38202913-3A641A7A-D7D4-4D0B-B32C-FF0583186B23Q38392673-6FED598B-5BF6-4E27-8A33-B2D07AEFE8A8Q38392679-17CFA2E5-7971-48B9-91A5-572F60505893Q38404422-AA1F3FA4-1C4D-41FC-978A-F3DEF2E6B051Q38697314-2FCD6BC4-811B-4C50-BFE7-41F0ADD993BFQ38944823-E11EA473-A16B-4A17-A75E-3E5452686FBEQ39040952-D5930A08-CEFE-43C4-BA73-FD8AF1E828F8Q39061903-B8D6F0C7-8BF8-4E2F-9C69-29D5E5E2D455Q40229471-FE5E4FDF-29EF-4410-A233-4AB3A832E2FFQ40539487-11C35DA7-31D9-487B-B616-BB633A9D5F48Q41809416-A98A775B-D9BF-4589-90BE-35BA9E73AD57
P2860
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@ast
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@en
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@nl
type
label
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@ast
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@en
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@nl
prefLabel
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@ast
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@en
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@nl
P2093
P2860
P921
P356
P1433
P1476
Dasatinib 100 mg once daily mi ...... s who develop pleural effusion
@en
P2093
H Jean Khoury
Kimmo Porkka
Ritwik Sinha
Ronald L Paquette
Yousif Matloub
P2860
P304
P356
10.1002/CNCR.24734
P407
P577
2010-01-01T00:00:00Z